COVID-19 is taking a huge toll among healthcare workers worldwide: researchers are warning that the coronavirus pandemic could inflict posttraumatic stress disorder on an unprecedented global scale. Here, the aim is to implement a novel treatment strategy – that yields long-term cure within a single treatment-session – for traumatised healthcare workers during COVID-19.
Angiotensin-II is a protein that plays a role in the development of acute lung injury in patients suffering from COVID-19 infection. Valsartan is a well-known, cheap drug in cardiovascular medicine with little side effects that blocks Angiotensin-II. This project investigates whether valsartan can prevent acute lung injury in COVID-19 infection.
The virus of the current corona pandemic manages to escape immunity. This project aims to make a vaccine based on conjugate vaccination technology to increase immunogenicity of the virus spike protein.
In plasma and vascular atherosclerotic specimens from patients with PAD the contribution of contact activation is investigated, in particular of kallikrein, to thrombosis using state of the art laboratory techniques. With specific inhibitors developed by Bayer, we dissect the different pathways and define the contribution of kallikrein to thrombus formation. The hope is to achieve an effective but safer (with regard to bleeding) antithrombotic strategy to protect PAD patients from myocardial infarction and thrombotic stroke.
All clinically available mAb are of the Immunoglobulin G class (IgG). In this project, IgA will be investigated in its unique capacity to activate neutrophils to kill cancer cells.
Many chronic diseases but also ageing are associated, and sometimes causal related, with gut problems such as enhanced leakiness, dysbiosis of microbiota, and inflammation. The aim is to demonstrate that cow milk-derived extracellular vesicles isolated by activity guided fractionation, have a beneficial effect on intestinal barrier function, gut microbiome and immunity.
The project will explore strategies to cure HIV via eliminating the HIV reservoir through induced cell death or through induced cell killing.
A library of peptides will be screened to identify suitable candidates that could efficiently exert the delivery of mRNA to Natural killer cells. This approach will then be used to generate engineered natural killer cells that could be used for cancer immune-therapy by using overexpression or gene editing strategies.
NPM1 is a gene that is often mutated in acute myeloid leukemia. Previously a receptor that recognises aberrant NPM1 and kills leukemic cells was found. In addition to this receptor, other receptors for different mutant NPM1 structures will be isolated and tested for their use to target leukemia by immunotherapy.
Drug development is often hampered due to the lack of reliable and relevant in vitro model systems to test newly developed medicinal compounds. Organoids are generated from adult stem cells and can faithfully recapitulate actual tissue responses to external stimuli. This project validated organoids application for drug development in the pharmaceutical industry.